Cogniguard Ltd., a clinical stage company that is developing noninvasive Vagal Nerve Stimulation (VNS) for the treatments for Alzheimer’s disease, Cognitive impairment and Epilepsy, updated that the European Patent Examiner, informed the company about its intention to issue a Notice of Allowance for its patent application for treating various neurological disorders using its synchronized nerve activation technology.
This is in continue to the United States Patent and Trademark Office (USPTO) Notice of Allowance issued a few months ago.